Latest News
The Aeroneb Solo nebulizer was nominated as a finalist in the category of Healthcare Technology Innovation at the Irish Healthcare Innovation Awards. This award recognises and rewards a significant and cutting-edge advance in independent healthcare provision - be it medical, financial, nursing or organisational technological advance of patient safety and patient welfare. Read more here
Aerogen has completed a management buyout (MBO) from its US parent, Nektar Therapeutics for an undisclosed amount.
“This deal empowers Aerogen to grow our business and expand our product offerings,” commented John Power, CEO, Aerogen. Aerogen has advanced negotiations in several exciting areas and plans to announce new partnerships with a number of US and European market leaders in both the medical field and commercial products area in the near future.
“This deal empowers Aerogen to grow our business and expand our product offerings,” commented John Power, CEO, Aerogen. Aerogen has advanced negotiations in several exciting areas and plans to announce new partnerships with a number of US and European market leaders in both the medical field and commercial products area in the near future.
The Aeroneb® Solo represents a new dimension in acute care nebulization and is the first single patient use, high efficiency nebulizer available to care givers.
